Neuland Laboratories Ltd (NEULANDLAB) Q1 FY27 Results Analysis: Revenue Surges 119%, Margin Above Sustainable Band

Neuland Laboratories Ltd's Q1 FY27 numbers came in strong, with revenue of Rs. 641.58 Cr (+119.15% YoY) and PAT growth of +962.40% YoY. Here's a quick read of what worked, what to watch, and what management said.

Quarter Snapshot

Neuland Laboratories reported a strong Q1 with revenue up 119% YoY to Rs.641.58 Cr and EBITDA margin of 35.59%, above its sustainable 25-30% band. The growth is driven by CDMO exports to Europe and USA, with export share rising to 87%. Capacity expansions at Unit 1 and a strategic collaboration with Gland Pharma support future growth. However, sequential revenue declined 17% from Q4's record, and India domestic API business contracted, highlighting lumpiness.

Key Investment Insights

Key Positives

• Revenue grew 119% YoY to Rs.641.58 Cr, the second-highest quarterly figure ever reported.
• EBITDA margin (management definition) came in at 35.59%, above the guided 25-30% sustainable band.
• PAT grew 962% YoY to Rs.147.67 Cr, with EPS at Rs.115.10.
• Europe revenue surged 221% YoY and USA revenue grew 204% YoY, driving the CDMO-led growth.
• Export revenue now constitutes 87% of total revenue, up from 66% in Q1FY26.
• Two capacity expansions at Unit 1 (total Rs.183.2 Cr) approved to address near-full utilization.

Risk Factors

• Revenue declined 17.35% QoQ from Q4 FY26's record Rs.776.25 Cr, consistent with management's warning about lumpy business.
• India revenue declined 15.83% YoY to Rs.83.26 Cr, indicating domestic generic API contraction.
• USA revenue declined 36.34% QoQ, reflecting lumpy shipment patterns in North America.
• Finance costs increased 52% YoY to Rs.6.97 Cr due to higher borrowings for capex.